Trial Profile
Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Adalimumab; Etanercept
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms ORAL Surveillance
- Sponsors Pfizer
- 03 Jun 2023 Results assessing the benefit/risk profile of tofacitinib by assessing efficacy in pts with RA with and without HxASCVD presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results of a post-hoc analysis assessing efficacy/safety in the SOC period in patients who discontinued study drug and started SOC treatment presented at the 24th Annual Congress of the European League Against Rheumatism
- 05 Dec 2022 Results of post hoc analysis, evaluating malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis , published in the Annals of the Rheumatic Diseases